会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 22. 发明申请
    • Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
    • 制备4-四唑基-4-苯基哌啶化合物的方法
    • US20070072909A1
    • 2007-03-29
    • US11495221
    • 2006-07-28
    • Kevin BrownTimothy DoyleJohn Whitehead
    • Kevin BrownTimothy DoyleJohn Whitehead
    • A61K31/454A61K31/165A61K31/41C07D403/02
    • C07D211/64C07D257/04C07D307/22C07D401/04
    • Methods, composition, and intermediates are disclosed that are useful for making 4-Tetrazolyl-4-phenylpiperidine Compounds according to Formula I, where Ar1 is —C3-C8 cycloalkyl, phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more R2 groups; Ar2 is phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more R2 groups; Z1 and Z2 are each independently a —(C1-C4 alkyl) group; R1 is —(CH2)nC(O)N(R3)(R4) where R3 and R4 are each independently H or —(C1-C4 alkyl); R2 is halogen, —C1-C3 alkyl, —O—(C1-C3 alkyl), —NH(C1-C3 alkyl) or —N(C1-C3 alkyl)2; n is an integer ranging from 1 to 4; m is an integer ranging from 0 to 4; and, in certain embodiments, the phenyl moiety attached to the 4-position of the piperidine ring of a compound according to Formula I can be optionally substituted with one or more R2 groups.
    • 公开了可用于制备根据式I的4-四唑基-4-苯基哌啶化合物的方法,组合物和中间体,其中Ar 1是-C 3 -C 3 - 苯基,萘基,蒽基,菲基或 - (5-7元)杂芳基,各自是未取代的或被一个或多个R 2 O 2基团取代; Ar 2是苯基,萘基,蒽基,菲基或 - (5-7-元)杂芳基,各自是未取代的或被一个或多个R 2 O 2基团取代; Z 1和Z 2各自独立地为 - (C 1 -C 4 -C 4烷基)基团; R 1是(CH 2)n C(O)N(R 3)(R 0) 其中R 3和R 4各自独立地为H或 - (C 1 -C 4)烷基, 烷基); R 2是卤素,-C 1 -C 3烷基,-O-(C 1 -C 3 - (C 1 -C 3烷基)或-NH(C 1 -C 3烷基)或-N(C 1 -C 3烷基) 3 烷基)2。 n为1〜4的整数; m为0〜4的整数; 并且在某些实施方案中,与式I化合物的哌啶环的4-位连接的苯基部分可任选被一个或多个R 2 O 2基团取代。
    • 28. 发明申请
    • Cysteine protease inhibitors
    • 半胱氨酸蛋白酶抑制剂
    • US20040229915A1
    • 2004-11-18
    • US10853408
    • 2004-05-24
    • MEDIVIR AB
    • Martin QuibellSteven TaylorUrszula GrabowskaMagnus NilssonVeronique Morrison
    • A61K031/452A61K031/4025A61K031/366C07D45/02
    • C07D405/12C07D307/22C07D307/32C07D307/68C07D307/85C07D309/14C07D309/30C07D405/14C07D409/12C07D409/14
    • of the formula (IV): 1 where: R1nullRnullC(O), RnullSO2, Rnullnulla bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b) and c) below; or Rnullnulla monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and/or c) and which may optionally bear one or two further substituents selected from group b); R4nullH, C1-7-alkyl, ArnullC1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7alkenyl,; R3nullC1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, ArnullC1-7-alkyl, Ar; R5nullC1-7-alkyl, halogen,ArnullC1-7-alkyl, C0-3-alkyl-CONR3R4 or a bulky amine R6 is H, C1-7-alkyl, ArnullC1-7-alkyl, C1-3-alkyl-SO2-Rix, C1-3-alkyl-C(O)nullNHRix or CH2XAr q is 0 or 1 have utility as inhibitors of cysteine proteases such as cathepsin K and falcipain.
    • 式(Ⅳ):其中:R1 = R'C(O),R'SO2,R'=含有0-4个杂原子的双环饱和或不饱和的8-12元环系,其选自S,O和 N,其任选被至多四个独立地选自以下的基团a),b)和c)中的取代基取代; 或R'=含有0-3个选自S,O和N的杂原子的单环,饱和或不饱和的5-7元环,该单环具有至少一个选自a)和/或c)的取代基,并且其中 可以任选地带有一个或两个其它选自组b)的取代基; R 4 = H,C 1-7 - 烷基,Ar-C 1-7 - 烷基,Ar,C 3-7 - 环烷基; C2-7烯基 R 3 = C 1-7 - 烷基,C 2 -C 7烯基,C 2 -C 7烯基,C 3-7 - 环烷基,Ar-C 1-7 - 烷基,Ar; R5 = C1-7烷基,卤素,Ar-C1-7 - 烷基,C0-3 - 烷基-CONR3R4或大体积的胺R6是H,C1-7 - 烷基,Ar-C1-7 - 烷基,C1-3 - 烷基-SO 2 -R 5,C 1-3 - 烷基-C(O)-NHR x或CH 2 XAr q为0或1可用作半胱氨酸蛋白酶如组织蛋白酶K和恶性蛋白酶的抑制剂。